nach oben

International Urology and Nephrology

Erschienen in:

01.01.2015 | Urology – Review

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis

verfasst von: Junjie Zhao, Weidong Xu, Zhensheng Zhang, Ruixiang Song, Shuxiong Zeng, Yinghao Sun, Chuanliang Xu

Erschienen in: International Urology and Nephrology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

The prognostic role of human epidermal growth factor receptor 2 (HER2) in bladder cancer (BCa) remains controversial. Thus, we conducted a meta-analysis to assess the prognostic significance of HER2 for patients with BCa.

Materials and methods

Systematically computerised searching in PubMed, Scopus database, Embase and Cochrane Library Database was conducted. Published studies comparing the prognosis in patients with BCa stratified by HER2 status were included, and relationships between HER2 positivity and gender, stage, grade, lymph node metastasis and survival were analysed.

Results

Nine studies with 2,242 eligible patients were identified. HER2 expression was significantly correlated with poor disease-specific survival [pooled hazard ratio (HR) 2.00; 95 % confidence interval (CI) 1.22–3.29; P = 0.006] and disease-free survival (pooled HR 1.68; 95 % CI 1.33–2.14; P < 0.0001) of patients with BCa. The positive rates of HER2 ranged from 27.8 to 85.2 % with a pooled positive rate of 41.2 % (1,006/2,442). HER2 expression was significantly associated with tumour grade [high grade vs. low grade: odds ratio (OR) 4.08; 95 % CI 1.29–12.93] and lymph node metastasis (positive vs. negative: OR 1.71; 95 % CI 1.07–2.75).

Conclusions

This meta-analysis indicated that HER2 expression is associated with poor prognosis. Thus, HER2 could serve as a useful biomarker for clinical prediction.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29PubMedCrossRef

Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182(6):2625–2630PubMedCrossRef

Stein JP, Skinner DG (2006) Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 24(3):296–304PubMedCrossRef

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820PubMedCrossRef

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRef

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Uehara T, Fujimoto M, Tsuruyama T, Date H, Haga H (2014) HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer. doi:10.1016/j.lungcan.2014.06.007

Bahmani B, Guerrero Y, Bacon D, Kundra V, Vullev VI, Anvari B (2014) Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells. Lasers Surg Med. doi:10.1002/lsm.22269

Drecoll E, Nitsche U, Bauer K, Berezowska S, Slotta-Huspenina J, Rosenberg R, Langer R (2014) Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. Int J Colorectal Dis 29(6):663–671PubMedCrossRef

Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kuhnel T, Brockhoff G, Schwarz S (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43(6):921–931PubMedCrossRef

10.

Zhau HE, Zhang X, von EAC, Scorsone K, Babaian RJ, Ro JY, Hung MC (1990) Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 3(5):254–257PubMedCrossRef

11.

Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322

12.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16PubMedCentralPubMedCrossRef

13.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605PubMedCrossRef

14.

Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH, Kim WK (2009) Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 20(8):1337–1343PubMedCrossRef

15.

O’Sullivan CC, Swain SM (2013) Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther 13(5):779–790PubMedCrossRef

16.

Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston TR, Tollefson MK, Jeffrey KR, Cheville JC (2014) Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol 27(5):758–764PubMedCrossRef

17.

Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106(8):1216–1222PubMedCrossRef

18.

Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, Kumar R (2008) Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40(2):321–327PubMedCrossRef

19.

Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, Sayk F, Feller AC, Bohle A (2002) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21(5):981–987PubMed

20.

Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN (2011) Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 60(2):350–357PubMedCrossRef

21.

Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma. Cancer 95(5):1009–1015PubMedCrossRef

22.

Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, Chopin D (1997) Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 25(1):9–17PubMedCrossRef

23.

Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66(2):113–119PubMedCrossRef

24.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed

25.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256PubMedCentralPubMedCrossRef

26.

Tsai YS, Tzai TS, Chow NH, Yang WH, Tong YC, Lin JS, Chang CC, Cheng HL, Lin YM (2003) Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int 71(3):262–270PubMedCrossRef

27.

Tsai YS, Tzai TS, Chow NH (2007) Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy. Urol Int 79(3):210–216PubMedCrossRef

28.

Rotterud R, Nesland JM, Berner A, Fossa SD (2005) Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 95(9):1344–1350PubMedCrossRef

29.

Olsson H, Fyhr IM, Hultman P, Jahnson S (2012) HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol 46(2):102–107PubMedCrossRef

30.

Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107(5):764–772PubMedCrossRef

31.

Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come. CA Cancer J Clin 60(4):244–272PubMedCrossRef

32.

MacLennan GT, Kirkali Z, Cheng L (2007) Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51(4):889–897 discussion 897–898PubMedCrossRef

33.

Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E (1997) The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 193(11–12):767–775PubMedCrossRef

34.

Chang BS, Kim HL, Yang XJ, Steinberg GD (2001) Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma. Urology 57(6):1063–1066 discussion 1066–1067PubMedCrossRef

35.

Prinsen CF, Klaassen CH, Thunnissen FB (2003) Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol 11(2):168–173PubMedCrossRef

36.

Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, Zhang S (2014) Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 89(1):73–111PubMedCrossRef

37.

Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ael-F A, Fujisawa M (2011) Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 29(5):495–501PubMedCrossRef

38.

Janane A, Hajji F, Ismail TO, Elondo JC, Ghadouane M, Ameur A, Abbar M, Bouzidi A (2011) Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence. Actas Urol Esp 35(4):189–194PubMedCrossRef

Titel: Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis
verfasst von: Junjie Zhao
Weidong Xu
Zhensheng Zhang
Ruixiang Song
Shuxiong Zeng
Yinghao Sun
Chuanliang Xu
Publikationsdatum: 01.01.2015
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-014-0866-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Characteristics of IgA nephropathy in advanced-age patients

The alteration of inflammatory markers and apoptosis on chronic prostatitis induced by estrogen and androgen

Predictors for and impact of high peritonitis rate in Taiwanese continuous ambulatory peritoneal dialysis patients

The Cradle of the Journal of International Urology and Nephrology

Comparison of estimated GFR and measured GFR in prospective living kidney donors